A phase 3 study of IFx-Hu2.0 first line therapy of patients with advanced Merkel cell carcinoma in sequence with pembrolizumab

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 09 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Oct 2024 According to a TuHURA Biosciences media release, company announced merger with Kintara Therapeutics, Inc. and the combined company will operate under the name "TuHURA Biosciences, Inc.''
17 Oct 2024 According to TuHURA Biosciences media release, The Company is preparing to initiate a single Phase 3 accelerated approval registration trial in the first half of 2025 for treatment of 1st line Merkel Cell carcinoma under SPA agreement with FDA.
03 Apr 2024 According to a Kintara Therapeutics, Inc. media release, Kintara Therapeutics and TuHURA Biosciences enter into definitive merger agreement.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com